Browse through our press and news section by category:

09.10.2018, Madrid, Spain

Co-creating polymer containers: SCHOTT enables patient-centered drug delivery devices

At this year’s CPhI Worldwide in Madrid, October 9th-11th, SCHOTT (booth 4B10) will present its capabilities to jointly develop cylindrical pharmaceutical containers made of cyclic olefin copolymer (COC) with partners such as device manufacturers. SCHOTT has a longstanding track record in manufacturing polymer pharma packaging and has produced more than 100 million individualized containers. Now, the company leverages this know-how and experience into the co-development of containers that meet the needs of the drug product, filling process and drug administration.
More and more drugs are administered in combination with a device with the aim to make the drug delivery process as simple and comfortable for the patient as possible. “So far, the drug delivery device had to be built around the available pharmaceutical packaging containers, restricting the possible device design”, explains Tom Van Ginneken, Global Product Manager at SCHOTT. “We are taking a new approach now towards co-development of a customized polymer container. This means the container is created so that it offers a perfect fit with the device without compromising on the device design.’’ 

Maximized design freedom
The design freedom to customize the COC container according to the new dimensions enables, for example, manufacturers of wearables to reduce the size or adapt the form of the wearable. This in turn supports a discrete, optimized and easy-to-use administration for the patient, no matter how diverse the requirements of the patient population are.

Improved time-to-market
The joint development process is based on a 4-stage sampling process. Each stage of the sampling process provides individualized containers for different purposes in the drug development stage: from quickly delivered containers for design freeze of the concept to containers out of a semi-automated production line for a faster drug registration process. In addition, existing Drug Master Files (DMF) with polymer and different rubber formulations are available, leading to faster and easier regulatory filing.

Strong track record
For over 20 years, SCHOTT has been gaining profound experience and knowledge in manufacturing polymer syringes. The SCHOTT TopPac® syringes are commercially available in more than 90 countries and are part of a comprehensive portfolio of glass and polymer pharmaceutical packaging.

SCHOTT is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials and technology expertise and offers a broad portfolio of high-quality products and intelligent solutions. SCHOTT is an innovative enabler for many industries, including the home appliance, pharma, electronics, optics, life sciences, automotive and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. The group maintains a global presence with production sites and sales offices in 33 countries. With its workforce of approximately 15,000 employees, sales of 2.05 billion euros were generated in fiscal year 2016/2017. The parent company, SCHOTT AG, has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment.
Press contact
Joana Kornblum
PR & Communication Assistant Manager
Pharma | Medical | Diagnostics
Hattenbergstraße 10
55122 Mainz
Phone: +49 6131/66-4073